Related Experiment Video
Updated: Sep 19, 2025
CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors
Published on: September 14, 2019
Optimized genomic editing of a common Duchenne muscular dystrophy mutation in patient-derived muscle cells and a new
Mateusz Z Durbacz1,2, Yu Zhang1,2,3, Hui Li1,2
1Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Abstract:
Duchenne muscular dystrophy (DMD) is a fatal X-linked, recessive disease caused by mutations in the DMD gene encoding dystrophin, a membrane-associated protein necessary for maintaining muscle structure and function. One of the common DMD mutations is the deletion of exon 52 (Δ52), which introduces a premature stop codon in exon 53, preventing the expression of functional dystrophin protein. Patients with this mutation could benefit from skipping or reframing exon 53 to restore the dystrophin open reading frame. In this study, we investigated the efficacy of single-cut CRISPR gene editing with Staphylococcus pyogenes Cas9 (SpCas9)-LRVQR to restore dystrophin expression in patient-derived induced pluripotent stem cells (iPSCs) and a newly generated humanized DMD mouse model. We compared two injection routes for adeno-associated virus (AAV) serotype 9 to deliver gene-editing components to neonatal mice: intraperitoneal (IP) and facial vein (FV) injection. We observed efficient restoration of dystrophin protein expression across multiple skeletal muscle groups and the heart. The AAV9-mediated CRISPR single-cut approach ameliorated key DMD hallmarks, including histopathological phenotypes, impaired grip strength, and elevated serum creatine kinase levels. Our optimized strategies for dystrophin restoration in humanized DMD mice with exon 52 deletion represent a promising treatment for DMD.
Insights
CRISPR gene editing successfully restored dystrophin protein in a Duchenne muscular dystrophy (DMD) mouse model. This approach shows promise for treating DMD by correcting the genetic defect and improving muscle function.
Area of Science:
- Biotechnology
- Genetics
- Molecular Biology
Background:
- Duchenne muscular dystrophy (DMD) is a fatal X-linked genetic disorder.
- Mutations in the DMD gene, such as exon 52 deletion, prevent functional dystrophin production, leading to muscle degeneration.
- Restoring the dystrophin open reading frame is a potential therapeutic strategy.
Purpose of the Study:
- To investigate the efficacy of single-cut CRISPR gene editing using Staphylococcus aureus Cas9 (SpCas9)-LRVQR.
- To restore dystrophin expression in patient-derived induced pluripotent stem cells (iPSCs) and a humanized DMD mouse model.
- To compare adeno-associated virus serotype 9 (AAV9) delivery routes for gene editing components in neonatal mice.
Main Methods:
- Utilized single-cut CRISPR-Cas9 gene editing technology.
- Employed adeno-associated virus serotype 9 (AAV9) for delivering gene-editing components.
- Administered AAV9 via intraperitoneal (IP) and facial vein (FV) injections in neonatal mice.
- Assessed dystrophin restoration and amelioration of DMD hallmarks in a humanized mouse model.
Main Results:
- Efficient restoration of dystrophin protein expression was observed in multiple skeletal muscles and the heart.
- The AAV9-mediated CRISPR single-cut approach ameliorated key DMD hallmarks.
- Histopathological phenotypes, impaired grip strength, and elevated serum creatine kinase levels were improved.
- Facial vein injection showed efficient delivery of gene-editing components.
Conclusions:
- Optimized CRISPR gene editing strategies effectively restore dystrophin in a relevant DMD mouse model.
- This approach holds promise as a potential therapeutic strategy for Duchenne muscular dystrophy patients with exon 52 deletions.
- Further development of AAV9-mediated delivery and CRISPR editing could advance DMD treatment options.
Related Concept Videos
01:16In-vitro Mutagenesis
01:21Satellite Stem Cells and Muscular Dystrophy